Evidence map›Paper›PMID 32222952›Full record

ReviewPain and therapy2020

An Evidence-Based Review of Fremanezumab for the Treatment of Migraine.

Ivan Urits, Gavin Clark, Daniel An, Bredan Wesp, Rebecca Zhou, Ariunzaya Amgalan, Amnon A Berger, Hisham Kassem, Anh L Ngo, Alan D Kaye and 3 more

Open access · goldAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Pain and therapy, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed, 1 pooled it
2.9field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed, 1 synthesis or guideline pooled it, 28 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Migraine and Its Treatment from the Medicinal Chemistry Perspective.ACS pharmacology & translational science · 2024
    Review
  5. Review
  6. Review
  7. Rimegepant for the treatment of migraine.Health psychology research · 2022
    Article
  8. Article
  9. Article
  10. Article
  11. Pharmacogenetics in Primary Headache Disorders.Frontiers in pharmacology · 2021
    Review
  12. Review
  13. Article
  14. Review
  15. Review
  16. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 7 institutions in 1 country.

Ivan UritsBeth Israel Deaconess Medical Center, Department of Anesthesiology, Critical Care, and Pain Medicine, Harvard Medical School, Boston, MA, USA. iurits@bidmc.harvard.edu.
Gavin ClarkGeorgetown University School of Medicine, Washington, DC, USA.
Daniel AnGeorgetown University School of Medicine, Washington, DC, USA.
Bredan WespGeorgetown University School of Medicine, Washington, DC, USA.
Rebecca ZhouGeorgetown University School of Medicine, Washington, DC, USA.
Ariunzaya AmgalanGeorgetown University School of Medicine, Washington, DC, USA.
Amnon A BergerBeth Israel Deaconess Medical Center, Department of Anesthesiology, Critical Care, and Pain Medicine, Harvard Medical School, Boston, MA, USA.
Hisham KassemDepartment of Anesthesiology, Mount Sinai Medical Center, Miami Beach, FL, USA.
Anh L NgoDepartment of Anesthesiology, Perioperative and Pain Medicine, Brigham and Women's Hospital, Boston, MA, USA.
Alan D KayeDepartment of Anesthesiology, Louisiana State University Health Shreveport, Shreveport, LA, USA.
Rachel J KayeMedical University of South Carolina, Charleston, SC, USA.
Elyse M CornettDepartment of Anesthesiology, Louisiana State University Health Shreveport, Shreveport, LA, USA.
Omar ViswanathValley Anesthesiology and Pain Consultants - Envision Physician Services, Phoenix, AZ, USA.
Georgetown University · USBeth Israel Deaconess Medical Center · USLouisiana State University in Shreveport · USBrigham and Women's Hospital · USCreighton University · USMedical University of South Carolina · USMount Sinai Medical Center · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Migraine headache is a common, chronic, debilitating disease with a complex etiology. Current therapy for migraine headache comprises either treatments targeting acute migraine pain or prophylactic therapy aimed at increasing the length of time between migraine episodes. Recent evidence suggests that calcium gene-related peptide (CGRP) is a critical component in the pathogenesis of migraines. Fremanezumab, a monoclonal antibody against CGRP, was recently approved by the Food and Drug Administration (FDA) after multiple studies showed that it was well-tolerated, safe, and effective in the treatment of migraines. Further research is needed to elucidate the long-term effects of fremanezumab and CGRP-antagonists in general, and additional data is required in less healthy patients to estimate its effects in these populations and potentially increase the eligible group of recipients. This is a comprehensive review of the current literature on the efficacy and safety of fremanezumab for the treatment of chronic migraine. In this review we provide an update on the epidemiology, pathogenesis, diagnosis, and current treatment of migraine, and summarize the evidence for fremanezumab as a treatment for migraine.

Indexed as

CGRPChronic painFremanezumabHeadacheMigraineMonoclonal antibody

Identifiers

PMID32222952
PMCPMC7203396
OpenAlexW3013251859

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.